NCT01647451已完成2 期
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Change in disease activity score based on 28 joints and c-reactive protein (DAS28-CRP)
研究概览
简要总结
This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of RA meeting the 2010 ACR (American College of Rheumatology) classification criteria, obtained at least 6 months prior to dosing with the trial product. (If the diagnosis was made prior to 2010, a diagnosis meeting the 1987 ACR classification criteria is acceptable)
- •Active RA characterised by DAS28-CRP (disease activity score based on 28 joints and c-reactive protein) equal to or above 4.5 and at least five tender and five swollen joints (can be the same joints) of the 28 joint count
- •Concomitant treatment with MTX above or equal to 15 mg/week for at least 4 months prior to screening, with stable dose of between or equal to 15 mg/week and 25 mg/week for at least 6 weeks prior to screening (MTX doses between 7.5 and 12.5 mg/week are allowed, if patient had intolerance to 15 mg/week)
- •Biologic naïve subjects or subjects having been treated with biologics for RA (biologic experienced) provided they meet one of the following criteria: a. Reason for discontinuation of biologic therapy was intolerance (e.g., unable to receive recommended doses or achieve adequate treatment duration because of drug related side effects), b. Discontinued biologic therapy for other reasons than lack of efficacy (primary or secondary failure) or intolerance (e.g., drug holiday)
排除标准
- •Body mass index (BMI) below or equal to 18.0 or above or equal to 38.0 kg/m^2
- •Subjects with rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome). Subjects with secondary Sjögren's syndrome or stable hypothyroidism are eligible
- •Any active or ongoing bacterial infections within 4 weeks prior to randomisation, unless treated and resolved with appropriate therapy (e.g., simple urinary tract infection)
- •Any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)
- •History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate therapy
研究组 & 干预措施
Active
Experimental
干预措施: NNC0114-0006 (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Change in disease activity score based on 28 joints and c-reactive protein (DAS28-CRP)
时间窗: Week 0, week 12
次要结局
- Terminal serum half-life (t½)(After second dose administration at week 6)
- ACR20/50/70 (20%, 50% or 70% improvement of ACR (American College of Rheumatology) score from baseline)(Week 12)
- Change in serum levels of total interleukin-21 (IL-21)(Up to week 12)
- Change in Health Assessment Questionnaire - Disability Index score (HAQ-DI)(Week 0, week 12)
- Incidence of adverse events (AEs)(Up to week 24)
- Incidence of antibodies against NNC0114-0006(Up to Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy of NNC109-0012 in Subjects With Active Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01282255Novo Nordisk A/S67
已完成
1 期
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersMetabolism and Nutrition DisorderObesityNCT00978393Novo Nordisk A/S49
已完成
2 期
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's DiseaseInflammationCrohn's DiseaseNCT01203631Janssen Research & Development, LLC78
已完成
2 期
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01223911Novo Nordisk A/S34
已完成
1 期
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian SubjectsHealthyDiabetesNCT00851773Novo Nordisk A/S84